| Literature DB >> 30093787 |
Takuma Tsuchiya1,2, Aki Kijima1, Yuji Ishii1, Shinji Takasu1, Yuh Yokoo1, Akiyoshi Nishikawa1, Tokuma Yanai2, Takashi Umemura1,3.
Abstract
Oxidative stress is well known as a key factor of chemical carcinogenesis. However, the actual role of oxidative stress in carcinogenesis, such as oxidative stress-related in vivo mutagenicity, remains unclear. It has been reported that 8-hydroxydeoxyguanosine (8-OHdG), an oxidized DNA lesion, might contribute to chemical carcinogenesis. Potassium bromate (KBrO3) and nitrofurantoin (NFT) are known as renal carcinogens in rats. Our previous studies showed an increase in mutant frequencies accompanied by an increased level of 8-OHdG in the kidneys of rodents following KBrO3 or NFT exposure. Furthermore, KBrO3 and NFT induced different types of gene mutations. Thus, in the present study, we performed reporter gene mutation assays and 8-OHdG measurements following KBrO3 or NFT exposure using Nrf2-proficient and Nrf2-deficient mice to clarify the relationship between KBrO3- or NFT-induced oxidative stress and subsequent genotoxicity. Administration of 1,500 ppm of KBrO3 in drinking water resulted in an increase in deletion mutations accompanied by an increase in 8-OHdG level, and administration of 2,500 ppm of NFT in diet induced an increase in guanine base substitution mutations without elevation of the 8-OHdG level in Nrf2-deficient mice. These results demonstrated that the formation of 8-OHdG, which resulted from the oxidizing potential of KBrO3, was directly involved in the increase in deletion mutations, although factors related to oxidative stress other than 8-OHdG might be crucial for NFT-induced guanine base substitution mutations. The present study provides new insight into oxidative stress-related in vivo mutagenicity.Entities:
Keywords: DNA damage; NF-E2-related factor 2; bromates; kidney; mutagens; nitrofurantoin
Year: 2018 PMID: 30093787 PMCID: PMC6077160 DOI: 10.1293/tox.2018-0024
Source DB: PubMed Journal: J Toxicol Pathol ISSN: 0914-9198 Impact factor: 1.628
Fig.
1.Growth curves for Nrf2+/+ or Nrf2−/− mice treated with KBrO3 or NFT for 4 weeks (A) or 13 weeks (B). For both genotypes, there were no significant differences in body weight between treated and untreated mice at either time point.
Final Body and Kidney Weights of Male Nrf2 or Nrf2−/−gpt Delta Mice Treated with KBrO3 or NFT for 4 or 13 Weeks
Fig. 2.Changes in mRNA levels of the Nrf2-target gene Nqo1 in the kidneys of Nrf2+/+ or Nrf2−/− mice treated with KBrO3 or NFT for 4 weeks (A) or 13 weeks (B). Values are means ± SD. *Significantly different (P<0.05) from the respective control group. **Significantly different (P<0.01) from the respective control group. ##Significantly different (P<0.01) from the respective Nrf2+/+ animals.
Fig. 3.8-OHdG levels in the kidneys of Nrf2+/+ or Nrf2−/− mice treated with KBrO3 or NFT for 4 weeks (A) or 13 weeks (B). Values are means ± SD. **Significantly different (P<0.01) from the respective control group. ††Significantly different (P<0.01) from the respective control group.
Gpt MFs in the Kidneys of Nrf2+/+ or Nrf2−/−gpt Delta Mice Treated with KBrO3 or NFT for 4 or 13 Weeks
Mmutation Spectra of gpt Mutant Colonies in the Kidneys of Nrf2+/+ Or Nrf2 Delta Mice Treated with KBrO3 or NFT for 4 Weeks
Mutation Spectra of gpt Mutant Colonies in the Kidneys of Nrf2+/+ or Nrf2 Delta Mice Treated with KBrO3 for 13 Weeks
Mutation Spectra of gpt Mutant Colonies in the Kidneys of Nrf2+/+ or Nrf2 Delta Mice Treated with NFT for 13 Weeks
Spi– MFs in the Kidneys of Nrf2+/+ or Nrf2 Delta Mice Treated with KBrO3 or NFT for 4 or 13 Weeks
Mutation Spectra of Spi– Plaques in the Kidneys of Nrf2+/+ or Nrf2 Delta Mice Treated with KBrO3 or NFT for 4 Weeks
Mutation Spectra of Spi– Plaques in the Kidneys of Nrf2+/+ or Nrf2 Delta Mice Treated with KBrO3 or NFT for 13 Weeks